Welcome to our dedicated page for Shineco news (Ticker: SISI), a resource for investors and traders seeking the latest updates and insights on Shineco stock.
Shineco, Inc. (NASDAQ: SISI) is a prominent player in the healthcare industry, focusing on developing and providing high-quality health products and services. Based in Bencroft Dassels Braughing, Ware, United Kingdom, Shineco aims to enhance the quality of life through safe and efficient health solutions. The company operates through its various subsidiaries, including Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd.
Shineco has made significant strides in the realm of medical technology. To date, it has successfully researched and developed over 33 vitro diagnostic reagents and related medical devices. In addition to medical products, the company also produces and sells nutritious food, contributing to overall health and well-being.
One of the notable achievements of Shineco is the invention of a new natural, active water-soluble phospholipid product extracted from soybean gum. This innovation utilizes pure physical extraction technology, a breakthrough that overcomes many limitations of traditional chemical extraction methods. This method avoids using chemical solvents, thus preserving the natural structure and activity of phospholipids.
The new product boasts high hydrophilicity, activity, purity, and human absorption efficiency. This groundbreaking technology promises to deliver high-quality phospholipids for various applications, including medical, functional foods, and beauty products. The first batch of these products was put into production in April 2024 at the Kaifeng production base.
Shineco's commitment to innovation is evident in its aim to tackle global challenges related to cellular nutrition. By providing natural active phospholipids, the company addresses issues related to cell health and nutrition, which are foundational to overall health.
In line with its vision, Shineco aims to establish a core value chain focusing on drugs, functional foods, and beauty products. The company projects that annual sales revenue from these efforts will reach $1 billion within three years.
For more information, visit Shineco's website at www.biosisi.com.
Shineco, Inc. announces the development of a revolutionary natural active water-soluble product extracted from soybean gum. This breakthrough technology aims to provide high-quality phospholipids essential for cell health and function. The product is set to address global nutritional deficiencies and offer diverse applications in medicine, functional foods, and beauty products.
Shineco, Inc. (NASDAQ: SISI) recently announced that its Cardiac 5-Minute Test has successfully passed quality inspection by China's NMPA, a significant milestone for its marketing in China. This test, developed by Shineco's subsidiary Biowin, is designed to quickly detect early-stage myocardial infarction, providing results in under 5 minutes, compared to over 20 minutes for existing tests. The NMPA's thorough evaluation focused on sensitivity, specificity, accuracy, and stability. Shineco aims to leverage this breakthrough in the Point-of-Care Testing market, which has a global potential of $3.5 billion.
FAQ
What is the current stock price of Shineco (SISI)?
What is the market cap of Shineco (SISI)?
What is Shineco, Inc.?
What recent innovations has Shineco introduced?
Where is Shineco based?
How many diagnostic reagents has Shineco developed?
What are the applications of Shineco's new phospholipid product?
When was the first batch of the new phospholipid product produced?
What does Shineco aim to achieve with its innovations?
What is the expected revenue from Shineco's new product lines?
How does Shineco's extraction technology benefit consumers?
Where can I find more information about Shineco?
